Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 65Kidney Neoplasms 18Neoplasms 6Neoplasm Metastasis 5Clear-cell metastatic renal cell carcinoma 5Kidney Diseases 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Melanoma 1Lung Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Merkel Cell 1Carcinoma 1Advanced Renal Cell Carcinoma (aRCC) 1Advanced Renal Cell Carcinoma (RCC) 1

Interventions

Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Malignancies × Axitinib × Genitourinary × Clear all
NCT01540526 2019-11-19

Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib

University of Wisconsin, Madison

Phase 1 Completed
24 enrolled
Genitourinary

Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡